Uterine cancer

Summary

Uterine cancer (MONDO:0002715) is a cancer (an umbrella term covering 7 Mondo subtypes) with 3 cohort genes (4 GWAS associations across 4 studies; 3 CIViC-evidence somatic drivers) and 146 clinical trials. Molecularly, BRCA1 Mutation OR BRCA2 Mutation confers sensitivity to Olaparib in Uterine Cancer (CIViC Level B); 2 further subtype–drug associations are mapped below. Top therapeutic interventions include loperamide, afatinib, and copanlisib.

At a glance

• Classification: Cancer
• Umbrella term: 7 Mondo subtypes
• Cohort genes: 3
• GWAS associations: 4
• Clinical trials: 146
• Precision-medicine evidence (CIViC): 3 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	uterine cancer
Mondo ID	MONDO:0002715
MeSH	D014594
DOID	DOID:363
ICD-11	1551596364
NCIT	C3552
SNOMED CT	371973000
UMLS	C0153567
MedGen	57791
Anatomy (UBERON)	UBERON:0000995
Is cancer (heuristic)	yes

Also known as: cancer of the uterus · cancer of uterus · malignant neoplasm of the uterus · malignant neoplasm of uterus · malignant tumor of the uterus · malignant tumor of uterus · malignant tumour of the uterus · malignant tumour of uterus · malignant uterine neoplasm · malignant uterine tumor · malignant uterine tumour · malignant uterus neoplasm · neoplasm of uterus · tumor of uterus · tumour of uterus · uterine cancer · uterine tumor · uterine tumour · uterus cancer · uterus neoplasm

Data availability: 4 GWAS associations (4 studies).

Disease family

An umbrella term covering 7 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer

Related subtypes (8): vaginal cancer, vulva cancer, fallopian tube cancer, adenocarcinofibroma, endometrioid adenocarcinoma, adenosarcoma, ovarian cancer, gestational choriocarcinoma

Subtypes (7): uterine adnexa cancer, placenta cancer, cervical cancer, uterine carcinoma, uterine corpus cancer, uterine carcinosarcoma, endometrial cancer

Genetics & variants

GWAS landscape

4 GWAS associations across 4 studies. Top hits map to 4 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs2899472	9e-12	MIR4713HG, CYP19A1	A	0.14
rs1740828	6e-11	BOLA2P3 - CASC15	A	0.12
rs9901746	7e-09	HNF1B	G	0.1
rs61374999	7e-07	MAST4	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90435608	Zhou W	2018	1,284	381,967	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90652194	Liu TY	2025	879	112,006	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90481507	Verma A	2024	316	32,638	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90399740	Zhou W	2022	83	5,786	Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	4

MAF distribution

Bucket	Variants
common (>=0.05)	3
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
intron_variant	3
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs2899472	15	51223858	C>A,T	0.212	intron_variant	MIR4713HG, CYP19A1	9e-12	Tier 4: intronic/intergenic
rs1740828	6	21648854	G>A	0.445	intergenic_variant	BOLA2P3 - CASC15	6e-11	Tier 4: intronic/intergenic
rs9901746	17	37743158	A>G	0.474	intron_variant	HNF1B	7e-09	Tier 4: intronic/intergenic
rs61374999	5	66948298	G>A		intron_variant	MAST4	7e-07	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 25 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
BRCA1	LoF	BLCA,BRCA,MEL,OVT	CIViC #6
BRCA2	LoF	BLCA,BRCA,CESC,CHOL,HCC,HNSC,LUSC,MBL,OVT,PAAD,PRAD,PROSTATE,RCC,VULVA	CIViC #7
ERBB2	Act	BLCA,BRCA,CESC,CHOL,COADREAD,EGC,ESCA,ESCC,LMS,LUAD,NSCLC,OVT,PRCC,READ,STAD,UCEC	CIViC #20

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
BRCA1	Orphanet:1331	Familial prostate cancer
BRCA1	Orphanet:1333	Familial pancreatic carcinoma
BRCA1	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA1	Orphanet:168829	Primary peritoneal carcinoma
BRCA1	Orphanet:227535	Hereditary breast cancer
BRCA1	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA1	Orphanet:694963	Inflammatory breast cancer
BRCA1	Orphanet:70567	Cholangiocarcinoma
BRCA1	Orphanet:84	Fanconi anemia
BRCA2	Orphanet:1331	Familial prostate cancer
BRCA2	Orphanet:1333	Familial pancreatic carcinoma
BRCA2	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA2	Orphanet:178	Chordoma
BRCA2	Orphanet:227535	Hereditary breast cancer
BRCA2	Orphanet:319462	Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations
BRCA2	Orphanet:440437	Familial colorectal cancer Type X
BRCA2	Orphanet:654	Nephroblastoma
BRCA2	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA2	Orphanet:694963	Inflammatory breast cancer
BRCA2	Orphanet:70567	Cholangiocarcinoma
BRCA2	Orphanet:84	Fanconi anemia
ERBB2	Orphanet:213726	Serous carcinoma of the corpus uteri
ERBB2	Orphanet:2800	Extramammary Paget disease
ERBB2	Orphanet:388	Hirschsprung disease
ERBB2	Orphanet:99976	Adenocarcinoma of the oesophagus and oesophagogastric junction

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BRCA1	HGNC:1100	ENSG00000012048	P38398	Breast cancer type 1 susceptibility protein	civic_evidence
BRCA2	HGNC:1101	ENSG00000139618	P51587	Breast cancer type 2 susceptibility protein	civic_evidence
ERBB2	HGNC:3430	ENSG00000141736	P04626	Receptor tyrosine-protein kinase erbB-2	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BRCA1	Breast cancer type 1 susceptibility protein	E3 ubiquitin-protein ligase that specifically mediates the formation of ‘Lys-6’-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage.
BRCA2	Breast cancer type 2 susceptibility protein	Involved in double-strand break repair and/or homologous recombination.
ERBB2	Receptor tyrosine-protein kinase erbB-2	Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding.

Protein-family classification

Druggable: 1 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	9.2×	0.313
Transcription factor	1	2.8×	0.482
Other/Unknown	1	0.6×	0.914

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BRCA1	Transcription factor	no	2.3.2.27	BRCT_dom, Znf_RING, BRCA1
BRCA2	Other/Unknown	no		BRCA2_repeat, NA-bd_OB-fold, BRCA2_OB_1
ERBB2	Kinase	yes	2.7.10.1	Rcpt_L-dom, Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	2
ventricular zone	2
primordial germ cell in gonad	1
secondary oocyte	1
lower esophagus mucosa	1
right uterine tube	1
sural nerve	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BRCA1	208	ubiquitous	marker	ventricular zone, male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad
BRCA2	184	ubiquitous	marker	male germ line stem cell (sensu Vertebrata) in testis, secondary oocyte, ventricular zone
ERBB2	276	ubiquitous	marker	lower esophagus mucosa, right uterine tube, sural nerve

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
ERBB2	9,659
BRCA1	9,064
BRCA2	4,839

Intra-cohort edges

A	B	Sources
BRCA1	BRCA2	string_interaction

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
ERBB2	P04626	63
BRCA1	P38398	33
BRCA2	P51587	14

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 95. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective homologous recombination repair (HRR) due to PALB2 loss of function	2	634.4×	1e-04	BRCA1, BRCA2
Diseases of DNA Double-Strand Break Repair	2	543.8×	1e-04	BRCA1, BRCA2
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	2	543.8×	1e-04	BRCA1, BRCA2
Resolution of D-Loop Structures	2	423.0×	2e-04	BRCA1, BRCA2
Diseases of DNA repair	2	380.7×	2e-04	BRCA1, BRCA2
Impaired BRCA2 binding to PALB2	2	304.5×	2e-04	BRCA1, BRCA2
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	2	282.0×	2e-04	BRCA1, BRCA2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	2	282.0×	2e-04	BRCA1, BRCA2
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	2	282.0×	2e-04	BRCA1, BRCA2
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	2	262.5×	2e-04	BRCA1, BRCA2
Homologous DNA Pairing and Strand Exchange	2	253.8×	2e-04	BRCA1, BRCA2
Homology Directed Repair	2	205.8×	2e-04	BRCA1, BRCA2
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	2	205.8×	2e-04	BRCA1, BRCA2
Impaired BRCA2 binding to RAD51	2	205.8×	2e-04	BRCA1, BRCA2
Resolution of D-loop Structures through Holliday Junction Intermediates	2	200.3×	2e-04	BRCA1, BRCA2
Meiosis	2	190.3×	2e-04	BRCA1, BRCA2
Presynaptic phase of homologous DNA pairing and strand exchange	2	181.3×	2e-04	BRCA1, BRCA2
DNA Double-Strand Break Repair	2	165.5×	3e-04	BRCA1, BRCA2
Reproduction	2	126.9×	4e-04	BRCA1, BRCA2
HDR through Homologous Recombination (HRR)	2	126.9×	4e-04	BRCA1, BRCA2
Meiotic recombination	2	86.5×	8e-04	BRCA1, BRCA2
DNA Repair	2	65.6×	0.001	BRCA1, BRCA2
Defective DNA double strand break response due to BRCA1 loss of function	1	1903.3×	0.002	BRCA1
Defective DNA double strand break response due to BARD1 loss of function	1	1903.3×	0.002	BRCA1
Impaired BRCA2 translocation to the nucleus	1	1268.9×	0.003	BRCA2
Impaired BRCA2 binding to SEM1 (DSS1)	1	1268.9×	0.003	BRCA2
PLCG1 events in ERBB2 signaling	1	951.7×	0.003	ERBB2
Drug-mediated inhibition of ERBB2 signaling	1	951.7×	0.003	ERBB2
Resistance of ERBB2 KD mutants to trastuzumab	1	951.7×	0.003	ERBB2
Resistance of ERBB2 KD mutants to sapitinib	1	951.7×	0.003	ERBB2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of DNA damage checkpoint	2	749.0×	2e-04	BRCA1, BRCA2
cellular response to ionizing radiation	2	274.0×	9e-04	BRCA1, BRCA2
double-strand break repair	2	135.4×	0.002	BRCA1, BRCA2
double-strand break repair via homologous recombination	2	104.0×	0.003	BRCA1, BRCA2
mitotic recombination-dependent replication fork processing	1	2808.7×	0.007	BRCA2
immature T cell proliferation in thymus	1	1123.5×	0.010	ERBB2
negative regulation of mammary gland epithelial cell proliferation	1	1123.5×	0.010	BRCA2
cellular response to indole-3-methanol	1	1123.5×	0.010	BRCA1
negative regulation of immature T cell proliferation in thymus	1	936.2×	0.010	ERBB2
ERBB2-ERBB4 signaling pathway	1	936.2×	0.010	ERBB2
chordate embryonic development	1	936.2×	0.010	BRCA1
negative regulation of centriole replication	1	802.5×	0.010	BRCA1
establishment of protein localization to telomere	1	702.2×	0.010	BRCA2
DNA strand resection involved in replication fork processing	1	702.2×	0.010	BRCA1
regulation of microtubule-based process	1	624.1×	0.010	ERBB2
DNA damage tolerance	1	561.7×	0.010	BRCA1
response to UV-C	1	561.7×	0.010	BRCA2
ERBB2-ERBB3 signaling pathway	1	561.7×	0.010	ERBB2
ERBB2-EGFR signaling pathway	1	561.7×	0.010	ERBB2
telomere maintenance via recombination	1	510.7×	0.010	BRCA2
homologous recombination	1	468.1×	0.011	BRCA1
enzyme-linked receptor protein signaling pathway	1	432.1×	0.011	ERBB2
negative regulation of intracellular estrogen receptor signaling pathway	1	374.5×	0.011	BRCA1
Schwann cell development	1	351.1×	0.011	ERBB2
negative regulation of gene expression via chromosomal CpG island methylation	1	351.1×	0.011	BRCA1
inner cell mass cell proliferation	1	330.4×	0.011	BRCA2
protein K6-linked ubiquitination	1	330.4×	0.011	BRCA1
centrosome duplication	1	312.1×	0.011	BRCA2
random inactivation of X chromosome	1	312.1×	0.011	BRCA1
negative regulation of reactive oxygen species metabolic process	1	312.1×	0.011	BRCA1

Therapeutics

Drugs indicated for this disease

0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Carboplatin	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bevacizumab, Celecoxib, Everolimus, Fluoroestradiol, Ifosfamide, Letrozole, Megestrol Acetate.

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 1

Druggability breadth: 2 of 3 evidence-associated genes (67%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
BRCA1	RIBOFLAVIN
ERBB2	CLOTRIMAZOLE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ERBB2	83	4
BRCA1	12	4
BRCA2	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
RIBOFLAVIN	4	BRCA1
DAUNORUBICIN HYDROCHLORIDE	4	BRCA1
TOPOTECAN HYDROCHLORIDE	4	BRCA1
DAUNORUBICIN	4	BRCA1
DOXORUBICIN HYDROCHLORIDE	4	BRCA1
MESALAMINE	4	BRCA1
DIPYRIDAMOLE	4	BRCA1
CLOTRIMAZOLE	4	ERBB2
ERLOTINIB HYDROCHLORIDE	4	ERBB2
PONATINIB	4	ERBB2
AFATINIB	4	ERBB2
LAPATINIB DITOSYLATE	4	ERBB2
SORAFENIB	4	ERBB2
NERATINIB	4	ERBB2
IBRUTINIB	4	ERBB2
AFATINIB DIMALEATE	4	ERBB2
CABOZANTINIB	4	ERBB2
DACOMITINIB	4	ERBB2
DACOMITINIB ANHYDROUS	4	ERBB2
VANDETANIB	4	ERBB2
TRIBROMSALAN	4	ERBB2
BOSUTINIB	4	ERBB2
BITHIONOL	4	ERBB2
ASTEMIZOLE	4	ERBB2
EBASTINE	4	ERBB2
OSIMERTINIB	4	ERBB2
BRIGATINIB	4	ERBB2
ACALABRUTINIB	4	ERBB2
ZANUBRUTINIB	4	ERBB2
TUCATINIB	4	ERBB2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
ERBB2	1,221	Binding:1136, Functional:79, ADMET:6
BRCA1	13	Binding:9, Functional:4

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
BRCA1	2.3.2.27	RING-type E3 ubiquitin transferase
ERBB2	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
ERBB2	1,221

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

28 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
RIBOFLAVIN	4	BRCA1
DAUNORUBICIN HYDROCHLORIDE	4	BRCA1
TOPOTECAN HYDROCHLORIDE	4	BRCA1
DAUNORUBICIN	4	BRCA1
DOXORUBICIN HYDROCHLORIDE	4	BRCA1
MESALAMINE	4	BRCA1
DIPYRIDAMOLE	4	BRCA1
CLOTRIMAZOLE	4	ERBB2
ERLOTINIB HYDROCHLORIDE	4	ERBB2
PONATINIB	4	ERBB2
LAPATINIB DITOSYLATE	4	ERBB2
SORAFENIB	4	ERBB2
NERATINIB	4	ERBB2
IBRUTINIB	4	ERBB2
AFATINIB DIMALEATE	4	ERBB2
CABOZANTINIB	4	ERBB2
DACOMITINIB	4	ERBB2
DACOMITINIB ANHYDROUS	4	ERBB2
VANDETANIB	4	ERBB2
TRIBROMSALAN	4	ERBB2
BOSUTINIB	4	ERBB2
BITHIONOL	4	ERBB2
ASTEMIZOLE	4	ERBB2
EBASTINE	4	ERBB2
BRIGATINIB	4	ERBB2
ACALABRUTINIB	4	ERBB2
ZANUBRUTINIB	4	ERBB2
TUCATINIB	4	ERBB2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	BRCA1, ERBB2
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	BRCA2

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
BRCA2	0	BRCA1

Clinical trials & evidence

Clinical trials

Clinical trials: 146.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	86
PHASE2	31
PHASE1/PHASE2	11
PHASE1	9
PHASE4	5
EARLY_PHASE1	2
PHASE2/PHASE3	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01432015	PHASE4	COMPLETED	Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
NCT01492179	PHASE4	COMPLETED	Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management.
NCT01953107	PHASE4	COMPLETED	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
NCT01962272	PHASE4	COMPLETED	The Effect of Nutritional Counseling for Cancer Patients
NCT03423082	PHASE4	TERMINATED	Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.
NCT03285802	PHASE2/PHASE3	COMPLETED	Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
NCT04849858	PHASE3	TERMINATED	Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
NCT02465060	PHASE2	ACTIVE_NOT_RECRUITING	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT03476681	PHASE1/PHASE2	RECRUITING	Study of NEO-201 in Solid Tumors Expansion Cohorts
NCT03668340	PHASE2	ACTIVE_NOT_RECRUITING	AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
NCT05559879	PHASE1/PHASE2	RECRUITING	Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT05579366	PHASE1/PHASE2	RECRUITING	Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05758688	PHASE2	RECRUITING	PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
NCT05864144	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT05916196	PHASE2	RECRUITING	[18F]FES PET/.CT in Uterine Cancer
NCT06040970	PHASE1/PHASE2	RECRUITING	Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
NCT06369155	PHASE2	RECRUITING	Azenosertib in Uterine Serous Carcinoma: Biomarker Study
NCT06492070	PHASE2	RECRUITING	Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
NCT06677190	PHASE2	RECRUITING	Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
NCT00147680	PHASE2	COMPLETED	Uterine Papillary Serous Cancer (UPSC) Trial
NCT00231829	PHASE2	TERMINATED	A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers
NCT00231842	PHASE2	COMPLETED	Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
NCT00231868	PHASE2	COMPLETED	A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
NCT00275353	PHASE2	COMPLETED	Effectiveness of an Individualized Symptom Education Program (ISEP)
NCT00284427	PHASE2	COMPLETED	Safety of Antioxidants During GYN Cancer Care
NCT00506779	PHASE1/PHASE2	TERMINATED	Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
NCT00582205	PHASE2	TERMINATED	Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
NCT00584857	PHASE2	COMPLETED	A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
NCT00584909	PHASE2	TERMINATED	A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus
NCT00588640	PHASE1/PHASE2	COMPLETED	Study of D-Methadone in Patients With Chronic Pain
NCT00626561	PHASE2	TERMINATED	Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
NCT01163552	PHASE2	COMPLETED	Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
NCT01176500	PHASE1/PHASE2	WITHDRAWN	A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
NCT01399658	PHASE2	COMPLETED	Image-Guided Gynecologic Brachytherapy
NCT01650376	PHASE1/PHASE2	UNKNOWN	Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
NCT02095847	PHASE2	WITHDRAWN	High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection
NCT02349958	PHASE2	UNKNOWN	Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
NCT02725489	PHASE2	COMPLETED	Pilot Study of Durvalumab and Vigil in Advanced Women’s Cancers
NCT03073525	PHASE2	COMPLETED	A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
NCT03192059	PHASE2	COMPLETED	Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LOPERAMIDE	4	3
AFATINIB	4	2
COPANLISIB	4	2
DABRAFENIB	4	2
LAROTRECTINIB	4	2
APREPITANT	4	1
BELZUTIFAN	4	1
BINIMETINIB	4	1
CAPIVASERTIB	4	1
CEMIPLIMAB	4	1
CILOSTAZOL	4	1
CRIZOTINIB	4	1
DOSTARLIMAB	4	1
ERDAFITINIB	4	1
FERROUS FUMARATE	4	1
FLUOROURACIL	4	1
FOSAPREPITANT	4	1
LIDOCAINE	4	1
MEGESTROL ACETATE	4	1
OLAPARIB	4	1
OSIMERTINIB	4	1
PALBOCICLIB	4	1
RELATLIMAB	4	1
SUNITINIB MALATE	4	1
TRAMETINIB	4	1
TRASTUZUMAB EMTANSINE	4	1
VISMODEGIB	4	1
DEFACTINIB	3	3
CURCUMIN	3	1
ESMETHADONE	3	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 3 predictive associations from 3 curated evidence items; also 2 diagnostic, 1 prognostic.

Molecular subtype	Therapy	Effect	Level	CIViC
BRCA1 Mutation OR BRCA2 Mutation	Olaparib	Sensitivity/Response	CIViC B	EID12766
ERBB2 Amplification	Trastuzumab + Pertuzumab	Sensitivity/Response	CIViC B	EID5986
EPHA2 Expression	Dasatinib + Trametinib	Sensitivity/Response	CIViC D	EID12576